All In Biotech

Drug Trial Radar · NCT06245213

A Study of ANAVEX3-71 in Adults With Schizophrenia

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Electrophysiology of ANAVEX3-71 in Adult Patients With Schizophrenia in a Multiple Ascending Dose Study (Part A), Followed by a Double-Blind, Randomized, Placebo-Controlled Study (Part B)

Last checked: Nov 20, 2026Latest source record: May 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

71

Actual

Start

Mar 15, 2024

Primary completion

Jun 30, 2025

Study completion Jun 30, 2025

Sponsor

Lead sponsor
Anavex Life Sciences Corp.Industry
Sponsor type
Industry
Collaborators
COGNISION; Cognitive Research Corporation; Hassman Research Institute
First posted
Feb 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • ANAVEX3-71 oral capsulesDrug

    ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.

  • Placebo oral capsulesDrug

    The placebo comparator for the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Single Dose Maximum Observed Plasma Concentration (Cmax)Time frame: Part A: Day 1
  2. Multiple Dose Maximum Observed Plasma Concentration (Cmax)Time frame: Part A: Day 1 and Day 9
  3. Cmax (steady state)Time frame: Part A: Day 1 and Day 9
  4. Tmax (steady state)Time frame: Part A: Day 1 and Day 9
  5. AUC (steady state)Time frame: Part A: Day 1 and Day 9
  6. AUC (single state)Time frame: Part A: Day 1 and Day 9
  7. CL/F (steady state)Time frame: Part A: Day 1 and Day 9
  8. Vz/F (steady state)Time frame: Part A: Day 1 and Day 9
  9. T1/2 (steady state)Time frame: Part A: Day 1 and Day 9
  10. Rac (steady state)Time frame: Part A: Day 1 and Day 9
  11. Rac, Cmax (steady state)Time frame: Part A: Day 1 and Day 9
  12. PTR (steady state)Time frame: Part A: Day 1 and Day 9
  13. Adverse EventsTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  14. Vital SignsTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  15. 12-lead ECG (RR interval)Time frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  16. 12-lead ECG (P wave)Time frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  17. 12-lead ECG (PR interval)Time frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  18. 12-lead ECG (PR segment)Time frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  19. 12-lead ECG (QRS complex)Time frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  20. 12-lead ECG (ST segment)Time frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  21. 12-lead ECG (T wave)Time frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  22. 12-lead ECG (QT interval)Time frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  23. Clinical Safety Labs - Renal PanelTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  24. Clinical Safety Labs - Hepatic PanelTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  25. Clinical Safety Labs - Lipid PanelTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  26. Clinical Safety Labs - Hematology PanelTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  27. Clinical Safety Labs - Urinalysis PanelTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  28. Clinical Safety Labs - Coagulation PanelTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  29. Brief Physical ExaminationTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  30. Brief Neurological ExaminationTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  31. AIMSTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  32. SASTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  33. BARSTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  34. CDSSTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  35. C-SSRSTime frame: Part A and Part B Screening to Safety Follow Up Visit; Up to 78 days (Part A) and Up to 114 days (Part B)
  36. EEG-ERP - Passive, Duration Deviant, Oddball ERPTime frame: Part A and Part B: Up to 12 days (Part A) and Up to 30 days (PartB)
  37. EEG-ERP - Active, Auditory, Oddball ERPTime frame: Part A and Part B: Up to 12 days (Part A) and Up to 30 days (PartB)
  38. EEG-ERP - Auditory Steady State ResponseTime frame: Part A and Part B: Up to 12 days (Part A) and Up to 30 days (PartB)
  39. EEG-ERP - Resting EEGTime frame: Part A and Part B: Up to 12 days (Part A) and Up to 30 days (PartB)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CenExel Hassman Research Institute

    Marlton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.